GLP-1 Medications and Metabolic Health

Summary

Watch Video | Download PDF

Glucagon-like peptide-1 (GLP-1) receptor agonists represent one of the most significant pharmaceutical advances in the treatment of obesity and type 2 diabetes. These medications can lead to significant weight loss, improve glycemic control, and reduce cardiometabolic risk for many patients. For some individuals, they are life-changing.

But the rapid shift toward a drug-first, long-term dependency model raises concerns. Obesity and metabolic disease are not the result of a GLP-1 deficiency, and medications alone do not address the underlying drivers of metabolic dysfunction. As GLP-1 use expands, lifestyle interventions are increasingly sidelined, despite growing evidence that effective dietary approaches—particularly low-carbohydrate and ketogenic diets—can improve metabolic health, reduce appetite, preserve lean mass, and help patients either avoid or discontinue medication.

Widespread reliance on GLP-1s also raises questions about durability, access, and long-term outcomes. Many patients experience weight loss plateaus, side effects, or loss of insurance coverage—yet there’s limited guidance on tapering, discontinuation, or sustainable alternatives. Data on lean muscle loss further underscore the need to prioritize body composition and long-term metabolic resilience, not just short-term weight reduction.

The Coalition for Metabolic Health (CMH) supports the responsible stewardship of GLP-1 medications—recognizing their value for certain patients, while rejecting the notion that lifelong pharmacotherapy should be the default solution. GLP-1s should be used as tools within a broader, evidence-based approach that includes effective lifestyle interventions, planning for off-ramps, and prioritizing durable metabolic health.

The Current Trajectory

Clinical guidelines and public messaging are increasingly positioning GLP-1 medications as an early—and in some cases default—intervention for individuals with obesity and metabolic dysfunction. In this model, meaningful lifestyle intervention is too often reduced to an afterthought or limited to generic, low-calorie advice that has fallen short of delivering durable metabolic improvements.

This trajectory carries several risks:

• Lifelong dependence: Many patients regain weight when GLP-1 therapy is discontinued, making long-term or indefinite use the default expectation.
• Limited durability: Many patients experience weight loss plateaus, partial response, or even non-response over time.
• Tolerability and side effects: Gastrointestinal side effects and other adverse effects lead many patients to reduce their dose or discontinue therapy.
• Access instability: Insurance churn, cost barriers, and supply disruptions can interrupt treatment.
• Clinical blind spots: Current guidance offers little direction on tapering, discontinuation, or alternative strategies when medications are no longer tolerated, affordable, or desired.

Healthcare policy should not assume that pharmaceutical treatment alone can solve a complex, multifactorial metabolic crisis.

What GLP-1s Do Well—and Where Their Limits Remain

GLP-1 medications are effective at reducing appetite and food intake, leading to weight loss and improvements in blood sugar control. For patients with type 2 diabetes and obesity, they represent some of the most effective pharmacologic tools currently available.

However, GLP-1s do not:

• Address the underlying dietary drivers of insulin resistance and metabolic dysfunction
• Restore metabolic flexibility or address the nutritional quality of food intake
• Preserve lean muscle mass
• Provide a clear pathway off medication once started

Weight loss alone is not a sufficient measure of metabolic health—particularly when near-term reductions on the scale come at the expense of long-term metabolic resilience.

Lean Muscle Loss and Long-Term Metabolic Outcomes

The loss of lean body mass is a particularly critical but under-addressed issue with GLP-1-induced weight loss. Studies suggest that a substantial portion—in some cases up to nearly 40%—of weight lost on GLP-1s may come from muscle and other lean tissue. While this is similar to calorie restricted diets or bariatric surgery, that doesn’t mean it is the optimal result.

This is cause for concern because muscle plays a central role in metabolic and long-term health, including:

• Insulin sensitivity and glucose disposal
• Long-term weight maintenance
• Physical function, aging resilience, and independence

Interventions shown to preserve lean mass—including resistance training and low-carbohydrate or ketogenic dietary approaches—shouldn’t be overlooked; they should be considered standard components of treatment.

The Lifestyle Blind Spot

A growing narrative that “lifestyle doesn’t work” reflects the failure of ineffective lifestyle recommendations, not the failure of lifestyle intervention itself. Generic advice to “eat less and move more” has predictably fallen short—but that should not be confused with evidence-based dietary strategies that directly target metabolic dysfunction.

Low-carbohydrate and ketogenic dietary approaches have consistently demonstrated:

• Significant weight loss and improved glycemic control
• Successful integrated diabetes management in many patients
• Reduced maladaptive eating
• Improved metabolic markers

Notably, one of the primary effects of GLP-1 medications—reduced appetite and lower calorie intake—is observed with well-formulated low-carbohydrate and ketogenic diets, without the requirement for lifelong pharmacotherapy.

Effective lifestyle interventions are a viable long-term off-ramp. Published clinical experience demonstrates that ketogenic diets, in particular, are effective at helping people discontinue GLP-1s while still maintaining their weight loss.

Yet, despite this mounting evidence, these dietary strategies remain largely excluded from standard treatment pathways, clinical guidelines, and reimbursement models.

Policy Principles

CMH recommends the following policy principles to guide GLP-1 use going forward:

1. GLP-1 medications should be used judiciously, not reflexively, and not as a stand-alone solution.
2. Lifestyle interventions must be foundational in the care of obesity and metabolic disease, as should a thorough workup for secondary causes of weight gain.
3. Low-carbohydrate and ketogenic dietary approaches, in particular, should be prioritized in treatment discussions and policy frameworks.
4. Preservation of lean muscle mass should be a point of emphasis in weight loss treatment.
5. Clear guidance on tapering and discontinuation is essential for responsible prescribing, as is a detailed discussion of risks and benefits.
6. Research funding for lifestyle interventions must be protected and expanded, not sidelined by an overreliance on pharmaceuticals.

Why This Matters

GLP-1 medications are poised to shape federal health spending, insurance design, clinical guidelines, and public expectations for decades. A drug-only model risks escalating costs, increasing dependency, and failing to deliver durable metabolic health.

A stewardship-based approach—one that integrates effective lifestyle interventions, preserves muscle, and prioritizes long-term health—offers a more sustainable path forward.

Contributors: Mariela Glandt, Tro Kalayjian, Caroline Roberts, Mark Cucazzella